---
document_datetime: 2025-12-02 05:14:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-krka.html
document_name: pemetrexed-krka.html
version: success
processing_time: 0.1000579
conversion_datetime: 2025-12-24 22:02:04.409916
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pemetrexed Krka

[RSS](/en/individual-human-medicine.xml/65691)

##### Withdrawn

This medicine's authorisation has been withdrawn

pemetrexed Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pemetrexed Krka](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 28 June 2024, the European Commission withdrew the marketing authorisation for Pemetrexed Krka (Pemetrexed) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, KRKA, d.d., Novo mesto, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pemetrexed Krka was granted marketing authorisation in the EU on 22 May 2018 for treatment of malignant pleural mesothelioma and non-small cell lung cancer treatment of malignant pleural mesothelioma and non-small cell lung cancer. The marketing authorisation was initially valid for a 5- year period. It was then granted unlimited validity in 2023. The product had not been marketed in the EU since 2022.

Pemetrexed Krka is a generic medicine of Alimta. There are other generic medicinal products of Alimta authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pemetrexed Krka is updated to indicate that the marketing authorisation is no longer valid.

Pemetrexed Krka : EPAR - Medicine overview

Reference Number: EMA/303183/2018

English (EN) (190.5 KB - PDF)

**First published:** 08/06/2018

**Last updated:** 30/07/2024

[View](/en/documents/overview/pemetrexed-krka-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-339)

български (BG) (250.58 KB - PDF)

**First published:**

30/07/2024

[View](/bg/documents/overview/pemetrexed-krka-epar-medicine-overview_bg.pdf)

español (ES) (189.79 KB - PDF)

**First published:**

30/07/2024

[View](/es/documents/overview/pemetrexed-krka-epar-medicine-overview_es.pdf)

čeština (CS) (231.54 KB - PDF)

**First published:**

30/07/2024

[View](/cs/documents/overview/pemetrexed-krka-epar-medicine-overview_cs.pdf)

dansk (DA) (182.58 KB - PDF)

**First published:**

30/07/2024

[View](/da/documents/overview/pemetrexed-krka-epar-medicine-overview_da.pdf)

Deutsch (DE) (191.75 KB - PDF)

**First published:**

30/07/2024

[View](/de/documents/overview/pemetrexed-krka-epar-medicine-overview_de.pdf)

eesti keel (ET) (174.84 KB - PDF)

**First published:**

30/07/2024

[View](/et/documents/overview/pemetrexed-krka-epar-medicine-overview_et.pdf)

ελληνικά (EL) (264.1 KB - PDF)

**First published:**

30/07/2024

[View](/el/documents/overview/pemetrexed-krka-epar-medicine-overview_el.pdf)

français (FR) (189.86 KB - PDF)

**First published:**

30/07/2024

[View](/fr/documents/overview/pemetrexed-krka-epar-medicine-overview_fr.pdf)

hrvatski (HR) (210.17 KB - PDF)

**First published:**

30/07/2024

[View](/hr/documents/overview/pemetrexed-krka-epar-medicine-overview_hr.pdf)

italiano (IT) (185.41 KB - PDF)

**First published:**

30/07/2024

[View](/it/documents/overview/pemetrexed-krka-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (214.99 KB - PDF)

**First published:**

30/07/2024

[View](/lv/documents/overview/pemetrexed-krka-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (223.82 KB - PDF)

**First published:**

30/07/2024

[View](/lt/documents/overview/pemetrexed-krka-epar-medicine-overview_lt.pdf)

magyar (HU) (214.01 KB - PDF)

**First published:**

30/07/2024

[View](/hu/documents/overview/pemetrexed-krka-epar-medicine-overview_hu.pdf)

Malti (MT) (234.27 KB - PDF)

**First published:**

30/07/2024

[View](/mt/documents/overview/pemetrexed-krka-epar-medicine-overview_mt.pdf)

Nederlands (NL) (192.22 KB - PDF)

**First published:**

30/07/2024

[View](/nl/documents/overview/pemetrexed-krka-epar-medicine-overview_nl.pdf)

polski (PL) (223.52 KB - PDF)

**First published:**

30/07/2024

[View](/pl/documents/overview/pemetrexed-krka-epar-medicine-overview_pl.pdf)

português (PT) (189.6 KB - PDF)

**First published:**

30/07/2024

[View](/pt/documents/overview/pemetrexed-krka-epar-medicine-overview_pt.pdf)

română (RO) (230.93 KB - PDF)

**First published:**

30/07/2024

[View](/ro/documents/overview/pemetrexed-krka-epar-medicine-overview_ro.pdf)

slovenčina (SK) (220.49 KB - PDF)

**First published:**

30/07/2024

[View](/sk/documents/overview/pemetrexed-krka-epar-medicine-overview_sk.pdf)

slovenščina (SL) (212.99 KB - PDF)

**First published:**

30/07/2024

[View](/sl/documents/overview/pemetrexed-krka-epar-medicine-overview_sl.pdf)

Suomi (FI) (175 KB - PDF)

**First published:**

30/07/2024

[View](/fi/documents/overview/pemetrexed-krka-epar-medicine-overview_fi.pdf)

svenska (SV) (178.45 KB - PDF)

**First published:**

30/07/2024

[View](/sv/documents/overview/pemetrexed-krka-epar-medicine-overview_sv.pdf)

Pemetrexed Krka : EPAR - Risk-management-plan summary

English (EN) (185.35 KB - PDF)

**First published:** 08/06/2018

**Last updated:** 30/07/2024

[View](/en/documents/rmp-summary/pemetrexed-krka-epar-risk-management-plan-summary_en.pdf)

## Product information

Pemetrexed Krka : EPAR - Product Information

English (EN) (1.17 MB - PDF)

**First published:** 08/06/2018

**Last updated:** 30/07/2024

[View](/en/documents/product-information/pemetrexed-krka-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-907)

български (BG) (1.81 MB - PDF)

**First published:**

30/07/2024

[View](/bg/documents/product-information/pemetrexed-krka-epar-product-information_bg.pdf)

español (ES) (959.81 KB - PDF)

**First published:**

30/07/2024

[View](/es/documents/product-information/pemetrexed-krka-epar-product-information_es.pdf)

čeština (CS) (1.48 MB - PDF)

**First published:**

30/07/2024

[View](/cs/documents/product-information/pemetrexed-krka-epar-product-information_cs.pdf)

dansk (DA) (988.47 KB - PDF)

**First published:**

30/07/2024

[View](/da/documents/product-information/pemetrexed-krka-epar-product-information_da.pdf)

Deutsch (DE) (1.4 MB - PDF)

**First published:**

30/07/2024

[View](/de/documents/product-information/pemetrexed-krka-epar-product-information_de.pdf)

eesti keel (ET) (1.22 MB - PDF)

**First published:**

30/07/2024

[View](/et/documents/product-information/pemetrexed-krka-epar-product-information_et.pdf)

ελληνικά (EL) (1.51 MB - PDF)

**First published:**

30/07/2024

[View](/el/documents/product-information/pemetrexed-krka-epar-product-information_el.pdf)

français (FR) (1.49 MB - PDF)

**First published:**

30/07/2024

[View](/fr/documents/product-information/pemetrexed-krka-epar-product-information_fr.pdf)

hrvatski (HR) (1.16 MB - PDF)

**First published:**

30/07/2024

[View](/hr/documents/product-information/pemetrexed-krka-epar-product-information_hr.pdf)

íslenska (IS) (1.44 MB - PDF)

**First published:**

30/07/2024

[View](/is/documents/product-information/pemetrexed-krka-epar-product-information_is.pdf)

italiano (IT) (1.04 MB - PDF)

**First published:**

30/07/2024

[View](/it/documents/product-information/pemetrexed-krka-epar-product-information_it.pdf)

latviešu valoda (LV) (1010.42 KB - PDF)

**First published:**

30/07/2024

[View](/lv/documents/product-information/pemetrexed-krka-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.29 MB - PDF)

**First published:**

30/07/2024

[View](/lt/documents/product-information/pemetrexed-krka-epar-product-information_lt.pdf)

magyar (HU) (1.15 MB - PDF)

**First published:**

30/07/2024

[View](/hu/documents/product-information/pemetrexed-krka-epar-product-information_hu.pdf)

Malti (MT) (1.41 MB - PDF)

**First published:**

30/07/2024

[View](/mt/documents/product-information/pemetrexed-krka-epar-product-information_mt.pdf)

Nederlands (NL) (1.12 MB - PDF)

**First published:**

30/07/2024

[View](/nl/documents/product-information/pemetrexed-krka-epar-product-information_nl.pdf)

norsk (NO) (1.2 MB - PDF)

**First published:**

30/07/2024

[View](/no/documents/product-information/pemetrexed-krka-epar-product-information_no.pdf)

polski (PL) (1.27 MB - PDF)

**First published:**

30/07/2024

[View](/pl/documents/product-information/pemetrexed-krka-epar-product-information_pl.pdf)

português (PT) (1013.61 KB - PDF)

**First published:**

30/07/2024

[View](/pt/documents/product-information/pemetrexed-krka-epar-product-information_pt.pdf)

română (RO) (1.11 MB - PDF)

**First published:**

30/07/2024

[View](/ro/documents/product-information/pemetrexed-krka-epar-product-information_ro.pdf)

slovenčina (SK) (1.11 MB - PDF)

**First published:**

30/07/2024

[View](/sk/documents/product-information/pemetrexed-krka-epar-product-information_sk.pdf)

slovenščina (SL) (1.24 MB - PDF)

**First published:**

30/07/2024

[View](/sl/documents/product-information/pemetrexed-krka-epar-product-information_sl.pdf)

Suomi (FI) (974.43 KB - PDF)

**First published:**

30/07/2024

[View](/fi/documents/product-information/pemetrexed-krka-epar-product-information_fi.pdf)

svenska (SV) (1.16 MB - PDF)

**First published:**

30/07/2024

[View](/sv/documents/product-information/pemetrexed-krka-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0009 15/02/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pemetrexed Krka : EPAR - All Authorised presentations

English (EN) (49.86 KB - PDF)

**First published:** 08/06/2018

**Last updated:** 30/07/2024

[View](/en/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-898)

български (BG) (68.99 KB - PDF)

**First published:**

30/07/2024

[View](/bg/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.24 KB - PDF)

**First published:**

30/07/2024

[View](/es/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_es.pdf)

čeština (CS) (62.75 KB - PDF)

**First published:**

30/07/2024

[View](/cs/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.73 KB - PDF)

**First published:**

30/07/2024

[View](/da/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (52.75 KB - PDF)

**First published:**

30/07/2024

[View](/de/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (52.62 KB - PDF)

**First published:**

30/07/2024

[View](/et/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (70.35 KB - PDF)

**First published:**

30/07/2024

[View](/el/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_el.pdf)

français (FR) (53.59 KB - PDF)

**First published:**

30/07/2024

[View](/fr/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (71.18 KB - PDF)

**First published:**

30/07/2024

[View](/hr/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (53.22 KB - PDF)

**First published:**

30/07/2024

[View](/is/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_is.pdf)

italiano (IT) (51.63 KB - PDF)

**First published:**

30/07/2024

[View](/it/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.92 KB - PDF)

**First published:**

30/07/2024

[View](/lv/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (66.5 KB - PDF)

**First published:**

30/07/2024

[View](/lt/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (49.95 KB - PDF)

**First published:**

30/07/2024

[View](/hu/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (74.34 KB - PDF)

**First published:**

30/07/2024

[View](/mt/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.29 KB - PDF)

**First published:**

30/07/2024

[View](/nl/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (43.67 KB - PDF)

**First published:**

30/07/2024

[View](/no/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.78 KB - PDF)

**First published:**

30/07/2024

[View](/pl/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_pl.pdf)

português (PT) (51.5 KB - PDF)

**First published:**

30/07/2024

[View](/pt/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.9 KB - PDF)

**First published:**

30/07/2024

[View](/ro/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.15 KB - PDF)

**First published:**

30/07/2024

[View](/sk/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (50.07 KB - PDF)

**First published:**

30/07/2024

[View](/sl/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.45 KB - PDF)

**First published:**

30/07/2024

[View](/fi/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (53.58 KB - PDF)

**First published:**

30/07/2024

[View](/sv/documents/all-authorised-presentations/pemetrexed-krka-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pemetrexed Krka Active substance pemetrexed disodium International non-proprietary name (INN) or common name pemetrexed Therapeutic area (MeSH)

- Carcinoma, Non-Small-Cell Lung
- Mesothelioma

Anatomical therapeutic chemical (ATC) code L01BA04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Malignant pleural mesothelioma**

Pemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

**Non-small cell lung cancer**

Pemetrexed Krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

## Authorisation details

EMA product number EMEA/H/C/003958

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

KRKA d.d.

Šmarješka cesta 6

Opinion adopted 22/03/2018 Marketing authorisation issued 22/05/2018 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pemetrexed Krka : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (253.52 KB - PDF)

**First published:** 02/10/2019

**Last updated:** 30/07/2024

[View](/en/documents/procedural-steps-after/pemetrexed-krka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Pemetrexed Krka : EPAR - Public assessment report

Reference Number: EMA/CHMP/225126/2018

English (EN) (832.58 KB - PDF)

**First published:** 08/06/2018

**Last updated:** 30/07/2024

[View](/en/documents/assessment-report/pemetrexed-krka-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Pemetrexed Krka

Adopted

Reference Number: EMA/CHMP/10762/2018

English (EN) (134.07 KB - PDF)

**First published:** 23/03/2018

**Last updated:** 30/07/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-pemetrexed-krka_en.pdf)

#### News on Pemetrexed Krka

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-march-2018) 23/03/2018

**This page was last updated on** 30/07/2024

## Share this page

[Back to top](#main-content)